Insomnia due to other mental disorder
Methodology & AI Transparency ⓘ
Insomnia due to other mental disorder Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Insomnia due to other mental disorder (ICD-10-CM F51.05), Insomnia, Sleep Apnea & Sleep Health protocols prioritize CBT-I behavioral sleep in Insomnia due to other mental disorder (F51.05: efficiency tracking) paired with baseline and interval Nocturnal Oxygen Saturation in Insomnia due to other mental disorder (F51.05: (SpO2)) assessment.
- 2 Real-world patient consensus: Mapped to Insomnia, Sleep Apnea & Sleep Health under ICD-10-CM F51.05 for Insomnia due to other mental disorder clinical workups.
- 3 Typical cash cost range: Differential triage of Insomnia due to other mental disorder (F51.05) utilizes CBT-I behavioral sleep in Insomnia due to other mental disorder (F51.05: efficiency tracking).
- 4 Top reported side effects / signs: Key Sleep Disorders biomarkers for Insomnia due to other mental disorder (F51.05): Nocturnal Oxygen Saturation in Insomnia due to other mental disorder (F51.05: (SpO2)) & Serum Ferritin (Restless in Insomnia due to other mental disorder (F51.05: Legs)) (> 75 ng/mL (F51.05)).
Ask our AI Specialists anything about Insomnia due to other mental disorder
What Is Insomnia due to other mental disorder?
For patients presenting with Insomnia due to other mental disorder (ICD-10-CM F51.05), Insomnia, Sleep Apnea & Sleep Health protocols prioritize CBT-I behavioral sleep in Insomnia due to other mental disorder (F51.05: efficiency tracking) paired with baseline and interval Nocturnal Oxygen Saturation in Insomnia due to other mental disorder (F51.05: (SpO2)) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Insomnia due to other mental disorder (F51.05) alters sleep disorders homeostasis through lateral hypothalamic orexin in Insomnia due to other mental disorder (F51.05: hyperarousal); clinical remission targets Serum Ferritin (Restless in Insomnia due to other mental disorder (F51.05: Legs)) within > 75 ng/mL (F51.05).
Common Symptoms & Clinical Signs
- • Presentation of Insomnia due to other mental disorder (F51.05): loud habitual snoring, in Insomnia due to other mental disorder (F51.05: witnessed breathing pauses,)
- • Secondary Insomnia due to other mental disorder clinical sign: daytime microsleeps, cognitive in Insomnia due to other mental disorder (F51.05: brain fog, or)
- • Symptom flares in Insomnia due to other mental disorder correlating with Nocturnal Oxygen Saturation in Insomnia due to other mental disorder (F51.05: (SpO2)) deviation outside >= 94% nadir > 90% (F51.05)
- • Functional sleep disorders impact requiring CBT-I behavioral sleep in Insomnia due to other mental disorder (F51.05: efficiency tracking) evaluation (F51.05)
Insomnia due to other mental disorder Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F51.05 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Insomnia, Sleep Apnea & Sleep Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Nocturnal Oxygen Saturation in Insomnia due to other mental disorder (F51.05: (SpO2)) | >= 94% nadir > 90% (F51.05) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin (Restless in Insomnia due to other mental disorder (F51.05: Legs)) | > 75 ng/mL (F51.05) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apnea-Hypopnea Index (AHI) [Insomnia due to other mental disorder F51.05] | < 5 events/hour (F51.05) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Insomnia due to other mental disorder
Treatment selection for Insomnia due to other mental disorder depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Insomnia due to other mental disorder)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Re-examining the factor structure of the trouble sleeping Severity Index (ISI): What a 1,956-Participant Study Found A 6-item two-factor scale had better psychometric properties than the 7-item scale in this patient sample. Journal of patient-reported outcomes • 2024-06-29 • Phase III Randomized Trial | N = 1,956 | 96/100 | PMID 38951287 ↗ |
| New Insights on Interventions for trouble sleeping in cancer patients and survivors-a: What a 6,528-Participant Study Found CBT-I is supported as a first-line treatment for trouble sleeping in cancer survivors, with significant benefits observed across sleep and non-sleep outcomes. JNCI cancer spectrum • 2024-04-30 • Meta-Analysis | N = 6,528 | 94/100 | PMID 38781520 ↗ |
| New Insights on Acute efficacy of fluoxetine versus sertraline and paroxetine in depression: What a 284-Participant Study Found These data show no significant differences in acute treatment efficacy and tolerability across fluoxetine, sertraline, and paroxetine in depression patients. Journal of clinical psychopharmacology • 2002-04-15 • Randomized Controlled Trial | N = 284 | 93/100 | PMID 11910258 ↗ |
| New Insights on Long-term effectiveness and safety of lemborexant in adults with trouble sleeping: What a 949-Participant Study Found LEM5 and LEM10 had significant benefit on sleep onset and sleep maintenance compared with placebo, and importantly, lemborexant effectiveness persisted at twelve months, suggesting that lemborexant may provide long-term... Sleep medicine • 2021-04-15 • Phase III Randomized Trial | N = 949 | 93/100 | PMID 33636648 ↗ |
| New Insights on Meaningful Within-Patient Change on the trouble sleeping Daytime Symptoms and: What a 930-Participant Study Found This analysis demonstrates the meaningful within-patient change for the IDSIQ total score and domain scores, that the instrument is sensitive to changes in the patient experience of trouble sleeping, and that it can be used in... Pharmaceutical medicine • 2023-07-15 • Phase III Randomized Trial | N = 930 | 93/100 | PMID 37286927 ↗ |
Insomnia due to other mental disorder Patient Community & “People Like Me” Threads
Filter Insomnia due to other mental disorder community threads and patient logs by age, biological sex, dosage, and treatment duration.